Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 antibody with neoadjuvant chemoradiotherapy in MSS LARC
NCT04411537Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Jul 2020
- Primary completion
- Apr 2022
- Countries
- 1
01
Overview
Phase 2, open-label trial in rectal cancer, sponsored by Fudan University. Primary endpoint: Pathologic Complete Response Rate. Status: unknown.
02
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT04411537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04411537.